Hot Investor Mandate: Corporate Venture Arm of Manufacturing Company With Evergreen Fund Invest in All Life Science Sectors, Including R&D Services

20 Jul

A corporate venture capital of a manufacturing company based in Asia makes 50% of their investments in life science and healthcare and has had multiple successful exits in the past. The firm is actively looking for early-stage investment opportunities in the space. The firm prefers to invest in earlier rounds and the sweet spot is Seed to Series B. The firm is an evergreen fund. Typical initial check size ranges from $250k to half a million, but the firm is able to allocate more depending on the deal size. The firm is open to other capital structures, such as convertible notes or SAFE. The firm typically co-invests more than leads but is open to both, and it seeks opportunities globally.

The firm is most interested in therapeutics, diagnostics, medical devices and digital health and biotech R&D Services (CDMO). The firm is agnostic to subsectors and indications. Some areas of interest include technologies that support clinical study or help identify new markers or targets. In terms of stages of development, the firm is open to pre-clinical stage companies, or even companies that are in the “idea phase” as long as the technology is sound and there is some proof of concept.

There is no specific company and management team requirement. The firm will consider a board seat or observer seat on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a comment